What Are GLP-1 Agonists and How Do They Support Weight Loss?

GLP-1 receptor agonists have revolutionised the approach to weight loss and diabetes management, offering powerful tools for individuals looking to improve their health.

But what are GLP-1 agonists, and how do they help with weight loss?

At TheraVita Health, we provide access to licensed, evidence-based treatments to help you achieve your goals.

Let’s explore these medications in detail.

What Are GLP-1 Agonists?

GLP-1 (Glucagon-Like Peptide-1) is a hormone naturally produced in your gut that plays a significant role in regulating appetite, blood sugar, and digestion. GLP-1 agonists are medications that mimic this hormone, enhancing its effects to promote weight loss and improve blood sugar control.

Examples of GLP-1 Agonists and Dual-Action Medications:

• Semaglutide (Wegovy®, Ozempic®)

• Liraglutide (Saxenda®)

• Tirzepatide (Mounjaro®)

Their main actions include:

1. Delaying stomach emptying – Helping you feel fuller for longer.

2. Reducing hunger signals – Suppressing appetite and minimising cravings.

3. Increasing insulin secretion – Supporting better blood sugar control after meals.

4. Suppressing glucagon production – Lowering blood sugar levels further.

While initially developed to treat type 2 diabetes, the appetite-regulating effects of GLP-1 agonists have made them a cornerstone in medical weight loss.

How Do GLP-1 Agonists Support Weight Loss?

GLP-1 agonists help with weight loss through several interconnected mechanisms:

1. Appetite Suppression

These medications work directly on the brain’s hypothalamus, which regulates appetite, to help reduce hunger and cravings.

2. Prolonged Fullness

By slowing gastric emptying, GLP-1 agonists extend the feeling of satiety after meals. This can prevent overeating and snacking.

3. Stabilised Blood Sugar

GLP-1 agonists promote steadier blood sugar levels, reducing energy dips and the resulting urge for sugary or high-calorie foods.

4. Promote Fat Loss

These medications selectively encourage fat loss while preserving lean muscle mass, which is vital for maintaining a healthy metabolism.

The Next Generation: Dual GLP-1 and GIP agonist

While GLP-1 agonists are effective, newer medications like tirzepatide (Brand name Mounjaro®) represent an exciting advancement. Tirzepatide is a dual receptor agonist, meaning it activates two receptors:

1. GLP-1 receptor – Promoting the same effects described previously, such as appetite suppression and improved insulin secretion.

2. GIP receptor (Glucose-Dependent Insulinotropic Polypeptide) – A second hormone receptor involved in regulating energy balance and fat metabolism.

What Makes Tirzepatide Unique?

The dual-action nature of tirzepatide enhances weight loss by combining the appetite-suppressing effects of GLP-1 activation with the additional metabolic benefits of GIP activation.

Key benefits of tirzepatide include:

1. Greater Weight Loss Potential

Clinical trials have shown that tirzepatide can result in significantly more weight loss compared to single-action GLP-1 agonists like semaglutide.

2. Enhanced Fat-Burning

By targeting GIP, tirzepatide improves the body’s ability to metabolise fat and use it as energy, accelerating fat loss.

3. Improved Glycemic Control

The dual receptor activation leads to even better control of blood sugar levels, making tirzepatide an excellent option for individuals with type 2 diabetes and those seeking weight loss support.

The Role of Clinical Evidence

Semaglutide has demonstrated remarkable weight loss results in clinical trials.

• In the STEP 1 trial, participants without diabetes who used semaglutide at a dose of 2.4 mg weekly experienced an average weight loss of 14.9% of their body weight over 68 weeks, compared to 2.4% in the placebo group.

• Semaglutide has also been shown to improve cardiometabolic markers, including reductions in waist circumference, blood pressure, and cholesterol levels.

Tirzepatide: Dual-Action Innovation

• In the SURMOUNT-1 trial, participants taking tirzepatide achieved weight loss of up to 22.5% of their body weight at the highest dose (15 mg weekly), compared to 2.4% with placebo.

• Tirzepatide’s dual action enhances fat metabolism and provides even greater appetite suppression.

All GLP-1 agonists have been shown to support long-term weight loss when combined with lifestyle changes such as following a healthy diet and regular exercise.

Who Can Benefit From These Medications?

GLP-1 agonists are licensed for individuals with:

• Obesity (BMI ≥30)

• Overweight (BMI ≥27) with related health conditions like high blood pressure, type 2 diabetes, or sleep apnea.

How TheraVita Health Can Help You

At TheraVita Health, we conduct a thorough consultation to determine the most suitable treatment for your needs, ensuring safety, personalisation and effectiveness.

Here’s how we can support you:

1. Free Online Consultation – Complete a detailed form about your weight loss goals and medical history.

2. Expert Guidance – Book a follow-up consultation with an experienced Pharmacist Prescriber who specialises in weight management.

3. Tailored Plans – Receive individualised medication, diet, and exercise plans to maximise your results.

4. Ongoing Support – Monthly follow-ups to monitor your progress and adjust your plan as needed.

Take the Next Step Towards a Healthier You

GLP-1 agonists like tirzepatide offer powerful tools for achieving sustainable weight loss. If you’re ready to transform your health, TheraVita Health is here to guide you.

Start your journey today by completing our free online consultation form. Let’s take the first step together toward a healthier, more confident you.

Disclaimer: GLP-1 agonists are prescription-only medications. Suitability depends on individual health circumstances and should be assessed by a qualified healthcare professional.

References

1. Astrup, A., Rössner, S., Van Gaal, L., et al. (2009). Effects of liraglutide in the treatment of obesity: A randomised, double-blind, placebo-controlled study. Lancet, 374(9701), 1606–1616. https://doi.org/10.1016/S0140-6736(09)61375-1

2. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183

3. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038

4. O’Neil, P. M., Birkenfeld, A. L., McGowan, B., et al. (2018). Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: A randomised, double-blind, placebo and active-controlled, dose-ranging study. Lancet Diabetes & Endocrinology, 6(9), 669–679. https://doi.org/10.1016/S2213-8587(18)30254-2

5. Kang, J. G., & Park, C. Y. (2012). Anti-obesity drugs: A review about their effects and safety. Diabetes & Metabolism Journal, 36(1), 13–25. https://doi.org/10.4093/dmj.2012.36.1.13

6. Singh, G., & Krauthamer, M. (2023). Semaglutide and liraglutide for chronic weight management: A meta-analysis. BMJ, 381, 567. https://doi.org/10.1136/bmj.m1302

7. Clinical Advisor. (2023). Efficacy of GLP-1 agonists for weight loss in adults without diabetes. Retrieved from https://www.clinicaladvisor.com

8. BMJ. (2023). Effects of GLP-1 receptor agonists on weight loss: Systematic review and meta-analysis of randomised controlled trials. Retrieved from https://www.bmj.com